Clinical Trial Update: Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation [Phase 4]

View source ↗

Summary

Phase 4 trial update for Sandostatin (octreotide LAR) evaluating potential clinical improvement via receptor occupation optimization in neuroendocrine tumors an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Syndrome
• Neuroendocrine Tumors

Drugs mentioned

• Sandostatin (Octreotide acetate)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Neuroendocrine Tumors, Carcinoid Syndrome | Phase 4 | Status: TERMINATED